The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Nichi-Iko to Launch Own Products in Thailand in October
August 22, 2014
- Carfilzomib Monotherapy Fails to Meet Primary Endpoint in PIII: Amgen, Onyx
August 22, 2014
- MTPC, AZ Ink Research Collaboration Deal in Diabetic Nephropathy
August 21, 2014
- Eisai Files Fycompa for Primary Generalized Tonic-Clonic Seizures in US, Europe
August 21, 2014
- Japan to See Grueling Battle for Free-Price Viagra Generics
August 20, 2014
- Launch of Daiichi Sankyo Espha’s Cravit Generics Not Yet Determined
August 20, 2014
- Daiichi Sankyo Starts PIII Study of Etanercept Biosimilar, Eying Approval in FY2016
August 20, 2014
- Approval Conditions Lifted for Tykerb: GSK
August 20, 2014
- Pfizer Reveals First Doctor Payments amid Delays in Disclosure
August 19, 2014
- Eisai Licenses Pariet Successor to Zeria
August 19, 2014
- Eisai Files for Regulatory Approval of Lenvatinib in US, Europe
August 19, 2014
- Announcement: Sales Excellence Japan 2014 to Be Held on October 14, 15
August 18, 2014
- Genzyme Japan Appoints Former Bausch & Lomb Japan President Ashikaga as Its New President
August 18, 2014
- Teva Receives Marketing Authorization for 4 APIs/9 Products
August 18, 2014
- Santen Files NDA for Cosopt Mini for Glaucoma and Ocular Hypertension
August 18, 2014
- GSK Seeks Japan Regulatory Approval for Colistin
August 14, 2014
- Ethical Drug Sales Edge 0.4% Higher in June: Crecon Report
August 14, 2014
- Matsumotokiyoshi Holdings to Transfer OTC Drug-Related Wholesale Business to Alfresa Healthcare
August 14, 2014
- Japan Pharma Market Loses Ground in April-June, Nexium Joins Top 10 List: IMS
August 12, 2014
- PIII Study of Halaven for Advanced NSCLC Fails to Improve OS: Eisai
August 12, 2014
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…